Conferences EASL 2016
Other Infections
EASL 2016: Hepatitis B Treatment Linked to Colorectal and Cervical Cancer
- Details
- Category: HBV Treatment
- Published on Friday, 03 June 2016 00:00
- Written by Liz Highleyman
People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have an overall higher rate of malignancies, but did show an increased incidence of colorectal and cervical cancer, underlining the need for regular screening, according to a study presented at the recent EASL International Liver Congress in Barcelona.
EASL 2016: WHO Issues New Hepatitis C Guidelines, EASL Guidelines Update Coming
- Details
- Category: HCV Treatment Guidelines
- Published on Sunday, 08 May 2016 00:00
- Written by Liz Highleyman
In April, coinciding with the International Liver Congress in Barcelona, the World Health Organization (WHO) released an update to its Guidelines for the Screening, Care and Treatment of Patients with Chronic Hepatitis C Infection. The guidelines promote the transition to newer, more effective direct-acting antiviral (DAA) medications that have the potential to cure most people living with hepatitis C. Also during the meeting the European Association for the Study of the Liver (EASL) announced it would update its hepatitis C treatment guidelines at a special conference in September.
EASL 2016: ABT-493 + ABT-530 Works Well for Patients Who Did Not Respond to Prior DAAs
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 03 May 2016 00:00
- Written by Michael Carter
An experimental combination of direct acting antivirals (DAAs) from AbbVie is effective and safe in patients with hepatitis C virus (HCV) genotype 1 who did not respond to previous DAA therapy, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona. Between 86% and 100% of patients achieved sustained virological response and the combination worked well in the context of pre-existing resistance mutations.
EASL 2016: Antiviral Therapy Linked to Less Liver Cancer and Death in People with Mild Hepatitis B
- Details
- Category: HBV Treatment
- Published on Sunday, 08 May 2016 00:00
- Written by Liz Highleyman
Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver inflammation -- a group generally not prioritized for treatment --according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona.
EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains
- Details
- Category: People Who Inject Drugs
- Published on Wednesday, 27 April 2016 00:00
- Written by Liz Highleyman
People on opiate substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier), leading to improvements in some aspects of quality of life, according to findings from the C-EDGE CO-STAR study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona. However, the same study saw several cases of hepatitis C virus (HCV) reinfection after a cure, suggesting a greater emphasis on prevention may be warranted.
EASL 2016: Cost of Eliminating Viral Hepatitis Must Consider Social as Well as Medical Factors
- Details
- Category: HCV Policy & Advocacy
- Published on Thursday, 05 May 2016 00:00
- Written by Keith Alcorn
Securing commitments from national governments to treat viral hepatitis, scale up prevention activities, and aim for elimination of hepatitis B and C by 2030 will require a broad coalition of forces -- and a sophisticated approach to proving the value of investing in elimination of viral hepatitis -- delegates heard at last month’s EASL International Liver Congress.
EASL 2016: Portugal's Roll-Out of Hepatitis C DAA Therapy Achieves Impressive Outcomes
- Details
- Category: HCV Treatment
- Published on Wednesday, 27 April 2016 00:00
- Written by Michael Carter
Roll-out of hepatitis C therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96% of treated patients had a sustained virological response (SVR) to therapy, with a 100% response rate seen in some sub-groups. Treatment also worked well for people with liver cirrhosis and treatment response was unaffected by HIV coinfection, previous hepatitis C therapy, or older age.
EASL 2016: Does Having HIV Affect Response to Hepatitis C Treatment?
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 04 May 2016 00:00
- Written by Liz Highleyman
A study from the U.S. Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral (DAA) therapy for hepatitis C, while a Spanish study showed that HIV/HCV coinfected people were less likely to be cured. These conflicting findings, presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona, indicate that the interactions between HIV and hepatitis C are still not fully understood.
EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 26 April 2016 00:00
- Written by Liz Highleyman
NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.
More Articles...
- EASL 2016: People Treated for Hepatitis C Have Unexpectedly High Rate of Liver Cancer Recurrence
- EASL 2016: AbbVie Pangenotypic Combination Achieves High Cure Rate for Genotype 3 Hepatitis C
- EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World Settings
- EASL 2016: How Generic Direct-Acting Antivirals Are Changing the Hepatitis C Treatment Landscape
- EASL 2016: Vaccines for HIV and Hepatitis C Could Potentially Be Administered Together
- EASL 2016: Emricasan May Improve Inflammation and Liver Function in People with Cirrhosis
- EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with Sofosbuvir/Ledipasvir
- Coverage of the 2016 EASL International Liver Congress
- EASL 2016: NorUrsodeoxycholic Acid Help Rare Bile Duct Disease with No Current Treatment
- EASL 2016: High Incidence of HCV Reinfection Among HIV+ Gay Men in Western Europe
- EASL 2016: Sofosbuvir/ Velpatasvir Cures 95% of HIV/HCV Coinfected People
- EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks
- EASL 2016: Sofosbuvir/ Ledipasvir for 6 Weeks Cures Acute Hepatitis C in HIV-Negative People
- EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys
- EASL 2016: Low-Cost Generic Hepatitis C Drugs Match Branded Products in Viral Response
- EASL 2016: Shifting Hepatitis C Treatment to Primary Care Providers Could Expand Availability
- EASL 2016: $300 Hepatitis C Combination with Ravidasvir to Enter Clinical Trials
- EASL 2016: Hepatitis C Treatment May Not Stop Progression to Advanced Liver Disease
- EASL 2016: Liver Associations Worldwide Call for Elimination of Viral Hepatitis
- EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients
- EASL 2016: International Liver Congress Underway this Week in Barcelona
Web Design and Development by